SEARCH

SEARCH BY CITATION

References

  • 1
    Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis. A widespread disease with unpredictable and life-threatening consequences. Eur Heart J 2004; 25: 1197207.DOI: 10.1016/j.ehj.2004.03.011
  • 2
    American Heart Association. Heart Disease and Stroke Statistics—2004 Update. Dallas, TX: American Heart Association, 2003.
  • 3
    Doris A, Ebmeier K, Shajahan P. Depressive illness. Lancet 1999; 354: 136975.
  • 4
    Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997; 349 (9063): 143642.
  • 5
    Rozanski A, Blumenthal JA, Kaplan J. Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy. Circulation 1999; 99: 2192217.
  • 6
    Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA. Depressive symptoms and health-related quality of life: the Heart and Soul Study. JAMA 2003; 290: 21521.
  • 7
    Lesperance F, Frasure-Smith N, Juneau M, Theroux P. Depression and 1-year prognosis in unstable angina. Arch Intern Med 2000; 160: 135460.
  • 8
    Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, Czajkowski SM, DeBusk R, Hosking J, Jaffe A, Kaufmann PG, Mitchell P, Norman J, Powell LH, Raczynski JM, Schneiderman N. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA 2003; 289: 310616.
  • 9
    Ford DE, Mead LA, Chang PP, Cooper-Patrick L, Wang NY, Klag MJ. Depression is a risk factor for coronary artery disease in men: the precursors study. Arch Intern Med 1998; 158: 14226.
  • 10
    Carney RM, Rich MW, Freedland KE, Saini J, TeVelde A, Simeone C, Clark K. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988; 50: 62733.
  • 11
    Ahern DK, Gorkin L, Anderson JL, Tierney C, Hallstrom A, Ewart C, Capone RJ, Schron E, Kornfeld D, Herd JA, Richardson DW, Folick MJ. Biobehavioral variables and mortality or cardiac arrest in the Cardiac Arrhythmia Pilot Study (CAPS). Am J Cardiol 1990; 66: 5962.
  • 12
    Ladwig KH, Kieser M, Konig J, Breithardt G, Borggrefe M. Affective disorders and survival after acute myocardial infarction. Results from the post-infarction late potential study. Eur Heart J 1991; 12: 95964.
  • 13
    Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995; 91: 9991005.
  • 14
    Barefoot JC, Schroll M. Symptoms of depression, acute myocardial infarction, and total mortality in a community sample. Circulation 1996; 93: 197680.
  • 15
    Denollet J, Brutsaert DL. Personality, disease severity, and the risk of long-term cardiac events in patients with a decreased ejection fraction after myocardial infarction. Circulation 1998; 97: 16773.
  • 16
    Kaufmann MW, Fitzgibbons JP, Sussman EJ, Reed JF, Einfalt JM, Rodgers JK, Fricchione GL. Relation between myocardial infarction, depression, hostility, and death. Am Heart J 1999; 138: 54954.
  • 17
    Welin C, Lappas G, Wilhelmsen L. Independent importance of psychosocial factors for prognosis after myocardial infarction. J Intern Med 2000; 247: 62939.
  • 18
    Bush DE, Ziegelstein RC, Tayback M, Richter D, Stevens S, Zahalsky H, Fauerbach JA. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001; 88: 33741.
  • 19
    Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, Van Eijk JT, Van Tilburg W. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry 2001; 58: 2217.
  • 20
    Shiotani I, Sato H, Kinjo K, Nakatani D, Mizuno H, Ohnishi Y, Hishida E, Kijima Y, Hori M. Depressive symptoms predict 12-month prognosis in elderly patients with acute myocardial infarction. J Cardiovasc Risk 2002; 9: 15360.
  • 21
    Carney RM, Blumenthal JA, Catellier D, Freedland KE, Berkman LF, Watkins LL, Czajkowski SM, Hayano J, Jaffe AS. Depression as a risk factor for mortality after acute myocardial infarction. Am J Cardiol 2003; 92: 127781.
  • 22
    Pfiffner D, Hoffmann A. Psychosocial predictors of death for low-risk patients after a first myocardial infarction: a 7-year follow-up study. J Cardiopulm Rehabil 2004; 24: 8793.
  • 23
    Jenkinson CM, Madeley RJ, Mitchell JR, Turner ID. The influence of psychosocial factors on survival after myocardial infarction. Public Health 1993; 107: 30517.
  • 24
    Carinci F, Nicolucci A, Ciampi A, Labbrozzi D, Bettinardi O, Zotti AM, Tognoni G. Role of interactions between psychological and clinical factors in determining 6-month mortality among patients with acute myocardial infarction. Application of recursive partitioning techniques to the GISSI-2 database. Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico. Eur Heart J 1997; 18: 83545.
  • 25
    Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Effects of depression and anxiety on mortality and quality-of-life 4 months after myocardial infarction. J Psychosom Res 2000; 49: 22938.
  • 26
    Lane D, Carroll D, Ring C, Beevers DG, Lip GY. Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety. Psychosom Med 2001; 63: 22130.
  • 27
    Mayou RA, Gill D, Thompson DR, Day A, Hicks N, Volmink J, Neil A. Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom Med 2000; 62: 2129.
  • 28
    Lauzon C, Beck CA, Huynh T, Dion D, Racine N, Carignan S, Diodati JG, Charbonneau F, Dupuis R, Pilote L. Depression and prognosis following hospital admission because of acute myocardial infarction. CMAJ 2003; 168: 54752.
  • 29
    Stewart RA, North FM, West TM, Sharples KJ, Simes RJ, Colquhoun DM, White HD, Tonkin AM. Depression and cardiovascular morbidity and mortality: cause or consequence? Eur Heart J 2003; 24: 202737.
  • 30
    Wassertheil-Smoller S, Shumaker S, Ockene J, Talavera GA, Greenland P, Cochrane B, Robbins J, Aragaki A, Dunbar-Jacob J. Depression and cardiovascular sequelae in postmenopausal women. Arch Intern Med 2004; 164: 28998.
  • 31
    Strik JJ, Lousberg R, Cheriex EC, Honig A. One year cumulative incidence of depression following myocardial infarction and impact on cardiac outcome. J Psychosom Res 2004; 56: 5966.
  • 32
    Steeds RP, Bickerton D, Smith MJ, Muthusamy R. Assessment of depression following acute myocardial infarction using the Beck depression inventory. Heart 2004; 90: 2178.
  • 33
    Lane D, Carroll D, Lip GY. Anxiety, depression, and prognosis after myocardial infarction: is there a causal association? J Am Coll Cardiol 2003; 42: 180810.
  • 34
    Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000; 20: 13740.
  • 35
    Panagiotakos DB, Pitsavos C, Chrysohoou C, Tsetsekou E, Papageorgiou C, Christodoulou G, Stefanadis C. Inflammation, coagulation, and depressive symptomatology in cardiovascular disease-free people; the ATTICA study. Eur Heart J 2004; 25: 4929.
  • 36
    Lesperance F, Frasure-Smith N, Theroux P, Irwin M. The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatry 2004; 161: 2717.
  • 37
    Broadley AJ, Korszun A, Jones CJ, Frenneaux MP. Arterial endothelial function is impaired in treated depression. Heart 2002; 88: 5213.
  • 38
    Carney RM, Blumenthal JA, Stein PK, Watkins L, Catellier D, Berkman LF, Czajkowski SM, O'Connor C, Stone PH, Freedland KE. Depression, heart rate variability, and acute myocardial infarction. Circulation 2001; 104: 20248.
  • 39
    Ziegelstein RC, Fauerbach JA, Stevens SS, Romanelli J, Richter DP, Bush DE. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction. Arch Intern Med 2000; 160: 181823.
  • 40
    Strik JJ, Denollet J, Lousberg R, Honig A. Comparing symptoms of depression and anxiety as predictors of cardiac events and increased health care consumption after myocardial infarction. J Am Coll Cardiol 2003; 42: 18017.
  • 41
    Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003; 108: 20549.
  • 42
    Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol 2003; 41 (4 Suppl. S): 7S14S.
  • 43
    Trip M, Cats VM, Van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 154954.
  • 44
    Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494502.
  • 45
    Nemeroff CB, Musselman DL. Are platelets the link between depression and ischemic heart disease? Am Heart J 2000; 140 (4 Suppl.): 5762.
  • 46
    Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, Marzec U, Harker LA, Nemeroff CB. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996; 153: 13137.
  • 47
    Laghrissi-thode F, Wagner WR, Pollock B, Johnson P, Finkel M. Elevated platelet factor 4 and B-thromboglobulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 1997; 42: 2905.
  • 48
    Lederbogen F, Gilles M, Maras A, Hamann B, Colla M, Heuser I, Deuschle M. Increased platelet aggregability in major depression? Psychiatry Res 2001; 102: 25561.
  • 49
    Berk M, Plein H. Platelet supersensitivity to thrombin stimulation in depression: a possible mechanism for the association with cardiovascular mortality. Clin Neuropharmacol 2000; 23: 1825.
  • 50
    Mori H, Koyama T, Yamashita I. Plateletalpha-2 adrenergic receptor-mediated phosphoinositide responses in endogenous depression. Life Sci 1991; 48: 7418.
  • 51
    Shimbo D, Child J, Davidson K, Geer E, Osende JI, Reddy S, Dronge A, Fuster V, Badimon JJ. Exaggerated serotonin-mediated platelet reactivity as a possible link in depression and acute coronary syndromes. Am J Cardiol 2002; 89: 3313.
  • 52
    Brusov OS, Beliaev BS, Katasonov AB, Zlobina GP, Factor MI, Lideman RR. Does platelet serotonin receptor supersensitivity accompany endogenous depression? Biol Psychiatry 1989; 25: 37581.
  • 53
    Wood K, Swade C, Abou-Saleh M, Coppen A. Peripheral serotonergic receptor sensitivity in depressive illness. J Affect Disord 1984; 7: 5965.
  • 54
    Hrdina PD, Bakish D, Ravindran A, Chudzik J, Cavazzoni P, Lapierre YD. Platelet serotonergic indices in major depression: up-regulation of 5-HT2A receptors unchanged by antidepressant treatment. Psychiatry Res 1997; 66: 7385.
  • 55
    Yates M, Leake A, Candy JM, Fairbairn AF, McKeith IG, Ferrier IN. 5HT2 receptor changes in major depression. Biol Psychiatry 1990; 27: 48996.
  • 56
    Schins A, Honig A, Crijns H, Baur L, Hamulyak K. Increased coronary events in depressed cardiovascular patients: 5-HT2A receptor as missing link? Psychosom Med 2003; 65: 72937.
  • 57
    Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex BH, Rundback JH, Fabunmi RP, Robertson RM, Loscalzo J. Atherosclerotic vascular disease conference: Writing Group III: pathophysiology. Circulation 2004; 109: 261725.
  • 58
    Benderly M, Graff E, Reicher-Reiss H, Behar S, Brunner D, Goldbourt U. Fibrinogen is a predictor of mortality in coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study Group. Arterioscler Thromb Vasc Biol 1996; 16: 3516.
  • 59
    Toss H, Lindahl B, Siegbahn A, Wallentin L. Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. Circulation 1997; 96: 420410.
  • 60
    Moss AJ, Goldstein RE, Marder VJ, Sparks CE, Oakes D, Greenberg H, Weiss HJ, Zareba W, Brown MW, Liang CS, Lichstein E, Little WC, Gillespie JA, Van Voorhees L, Krone RJ, Bodenheimer MM, Hochman J, Dwyer EM Jr, Arora R, Marcus FI, Watelet LF, Case RB. Thrombogenic factors and recurrent coronary events. Circulation 1999; 99: 251722.
  • 61
    Thompson SG, Kienast J, Pyke SD, Haverkate F, Van De Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995; 332: 63541.
  • 62
    Folsom AR, Qamhieh HT, Flack JM, Hilner JE, Liu K, Howard BV, Tracy RP. Plasma fibrinogen: levels and correlates in young adults. The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol 1993; 138: 102336.
  • 63
    Kop WJ, Gottdiener JS, Tangen CM, Fried LP, McBurnie MA, Walston J, Newman A, Hirsch C, Tracy RP.Inflammation and coagulation factors in persons > 65 years of age with symptoms of depression but without evidence of myocardial ischemia. Am J Cardiol 2002; 89: 41924.
  • 64
    Dentino AN, Pieper CF, Rao MK, Currie MS, Harris T, Blazer DG, Cohen HJ. Association of interleukin-6 and other biologic variables with depression in older people living in the community. J Am Geriatr Soc 1999; 47: 611.
  • 65
    Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 176772.
  • 66
    Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 83643.
  • 67
    Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ. Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 2430.
  • 68
    Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 2002; 90: 127983.
  • 69
    Suarez EC, Lewis JG, Krishnan RR, Young KH. Enhanced expression of cytokines and chemokines by blood monocytes to in vitro lipopolysaccharide stimulation are associated with hostility and severity of depressive symptoms in healthy women. Psychoneuroendocrinology 2004; 29: 111928.
  • 70
    Appels A, Bar FW, Bar J, Bruggeman C, De Baets M. Inflammation, depressive symptomatology, and coronary artery disease. Psychosom Med 2000; 62: 6015.
  • 71
    Vita JA, Treasure CB, Nabel EG, McLenachan JM, Fish D, Yeung AC, Vekshtein VI, Selywn AP, Ganz P. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81: 4917.
  • 72
    Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, Nour KR, Quyyumi AA. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106: 6538.
  • 73
    Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 26738.
  • 74
    Rajagopalan S, Brook R, Rubenfire M, Pitt E, Young E, Pitt B. Abnormal brachial artery flow-mediated vasodilation in young adults with major depression. Am J Cardiol 2001; 88: 1968.
  • 75
    Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Melledo JM. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004; 56: 12934.
  • 76
    Bailey JJ, Berson AS, Handelsman H, Hodges M. Utility of current risk stratification tests for predicting major arrhythmic events after myocardial infarction. J Am Coll Cardiol 2001; 38: 190211.
  • 77
    Vigo DE, Nicola Siri L, Ladron De Guevara MS, Martinez-Martinez JA, Fahrer RD, Cardinali DP, Masoli O, Guinjoan SM. Relation of depression to heart rate nonlinear dynamics in patients > or =60 years of age with recent unstable angina pectoris or acute myocardial infarction. Am J Cardiol 2004; 93: 75660.
  • 78
    Stein PK, Carney RM, Freedland KE, Skala JA, Jaffe AS, Kleiger RE, Rottman JN. Severe depression is associated with markedly reduced heart rate variability in patients with stable coronary heart disease. J Psychosom Res 2000; 48: 493500.
  • 79
    Carney RM, Saunders RD, Freedland KE, Stein P, Rich MW, Jaffe AS. Association of depression with reduced heart rate variability in coronary artery disease. Am J Cardiol 1995; 76: 5624.
  • 80
    The ENRICHD Investigators. Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. Am Heart J 2000; 139: 19.
  • 81
    DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000; 160: 21017.
  • 82
    Carney RM, Freedland KE, Eisen SA, Rich MW, Jaffe AS. Major depression and medication adherence in elderly patients with coronary artery disease. Health Psychol 1995; 14: 8890.
  • 83
    Lehto S, Koukkunen H, Hintikka J, Viinamaki H, Laakso M, Pyorala K. Depression after coronary heart disease events. Scand Cardiovasc J 2000; 34: 5803.
  • 84
    Horwitz RI, Viscoli CM, Berkman L, Donaldson RM, Horwitz SM, Murray CJ, Ransohoff DF, Sindelar J. Treatment adherence and risk of death after a myocardial infarction. Lancet 1990; 336 (8714): 5425.
  • 85
    Irvine J, Baker B, Smith J, Jandciu S, Paquette M, Cairns J, Connolly S, Roberts R, Gent M, Dorian P. Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Psychosom Med 1999; 61: 56675.
  • 86
    Frasure-Smith N, Lesperance F, Talajic M. The impact of negative emotions on prognosis following myocardial infarction: is it more than depression? Health Psychol 1995; 14: 38898.
  • 87
    Beck J. Cognitive Therapy: Basics and Beyond. New York, NY: Guilford Press, 1995.
  • 88
    Roose SP, Spatz E. Treatment of depression in patients with heart disease. J Clin Psychiatry 1999; 60 (Suppl. 20): 347.
  • 89
    Roose SP, Laghrissi-Thode F, Kennedy JS, Nelson JC, Bigger JT Jr, Pollock BG, Gaffney A, Narayan M, Finkel MS, McCafferty J, Gergel I. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 1998; 279: 28791.
  • 90
    Roose SP, Glassman AH, Attia E, Woodring S, Giardina EG, Bigger JT Jr. Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 1998; 155: 6605.
  • 91
    Strik JJ, Honig A, Lousberg R, Lousberg AH, Cheriex EC, Tuynman-Qua HG, Kuijpers PM, Wellens HJ, Van Praag HM. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 2000; 62: 7839.
  • 92
    Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KR, Van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002; 288: 7019.
  • 93
    Van Den Brink RH, Van Melle JP, Honig A, Schene AH, Crijns HJ, Lambert FP, Ormel J. Treatment of depression after myocardial infarction and the effects on cardiac prognosis and quality of life: rationale and outline of the Myocardial INfarction and Depression-Intervention Trial (MIND-IT). Am Heart J 2002; 144: 21925.
  • 94
    Krishnan KR. Comorbidity and depression treatment. Biol Psychiatry 2003; 53: 7016.
  • 95
    Schleifer SJ, Macari-Hinson MM, Coyle DA, Slater WR, Kahn M, Gorlin R, Zucker HD. The nature and course of depression following myocardial infarction. Arch Intern Med 1989; 149: 17859.
  • 96
    Lesperance F, Frasure-Smith N, Talajic M. Major depression before and after myocardial infarction: its nature and consequences. Psychosom Med 1996; 58: 99110.
  • 97
    Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 136877.
  • 98
    Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 17129.
  • 99
    Dichtl W, Dulak J, Frick M, Alber HF, Schwarzacher SP, Ares MP, Nilsson J, Pachinger O, Weidinger F. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 5863.
  • 100
    Musselman DL, Marzec UM, Manatunga A, Penna S, Reemsnyder A, Knight BT, Baron A, Hanson SR, Nemeroff CB. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000; 57: 87582.
  • 101
    Markovitz JH, Shuster JL, Chitwood WS, May RS, Tolbert LC. Platelet activation in depression and effects of sertraline treatment: an open-label study. Am J Psychiatry 2000; 157: 10068.
  • 102
    Serebruany VL, Glassman AH, Malinin AI, Nemeroff CB, Musselman DL, Van Zyl LT, Finkel MS, Krishnan KR, Gaffney M, Harrison W, Califf RM, O'Connor CM. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation 2003; 108: 93944.
  • 103
    Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57: 50733.
  • 104
    Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001; 43: 45362.
  • 105
    Geer E, Child J, Shimbo D, Maayani S, Reddy S, Badimon JJ, Fuster V. Comparative effects of paroxetine and nefazodone on human platelet aggregation and vascular reactivity. J Am Coll Cardiol 2000; 35 (Suppl. A): 266.
  • 106
    Shimbo D, Geer E, Child J, Dronge A, Farkouh M, Reddy S, Halperin J. The selective serotonin reuptake inhibitor paroxetine inhibits endothelial-dependent vasodilatation. J Am Coll Cardiol 2000; 35 (Suppl. A): 271.
  • 107
    Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, Stang P, Zhou XH, Hays R, Weinberger M. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001; 286: 294755.
  • 108
    Maes M, Song C, Lin AH, Bonaccorso S, Kenis G, De Jongh R, Bosmans E, Scharpe S. Negative immunoregulatory effects of antidepressants: inhibition of interferon-gamma and stimulation of interleukin-10 secretion. Neuropsychopharmacology 1999; 20: 3709.
  • 109
    Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 1128.
  • 110
    Anda RF, Williamson DF, Escobedo LG, Mast EE, Giovino GA, Remington PL. Depression and the dynamics of smoking. A national perspective. JAMA 1990; 264: 15415.
  • 111
    Rutledge T, Hogan BE. A quantitative review of prospective evidence linking psychological factors with hypertension development. Psychosom Med 2002; 64: 75866.
  • 112
    Talbot F, Nouwen A. A review of the relationship between depression and diabetes in adults: is there a link? Diabetes Care 2000; 23: 155662.